Özgün Araştırma

Original Article

Jinekoloji - Obstetrik ve Neonatoloji Tıp Dergisi The Journal of Gynecology - Obstetrics and Neonatology

DOI: 10.38136/jgon.1289766

İlk Trimesterde Monosit Sayısı ve Monosit Bazlı Kan Hücre İndekslerinin Gebeliğin İntrahepatik Kolestazı Gelişimi, Şiddeti ve Prognozunu Öngörmedeki Rolü

The Role of Monocyte Count and Monocyte Based Complete Blood Cell Indexes in Predicting the Development, Severity and Prognosis of Intrahepatic Cholestasis of Pregnancy in the First Trimester

BEDRİ SAKCAK¹ RAMAZAN DENİZLİ¹ NİHAT FARİSOĞULLARI¹ ZAHİD AĞAOĞLU¹ ATAKAN TANACAN¹ DİLEK SAHİN²

- Orcid ID: 0000-0003-0277-5072
- Orcid ID: 0000-0003-1128-7169
- Orcid ID: 0000-0002-7767-0657
- Orcid ID: 0000-0001-8726-1075
- Orcid ID: 0000-0001-8209-8248
- Orcid ID: 0000-0001-8567-9048

¹ Department of Obstetrics and Gynecology, Division of Perinatology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey
² University of Health Sciences, Department of Obstetrics and Gynecology, Division of Perinatology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey

ÖΖ

Amaç: İlk trimesterde gebeliğin intrahepatik kolestazının (GİK) öngörüsünde monosit sayısı ve monosit bazlı kan hücre indekslerinin etkisini değerlendirmek.

Gereçler ve Yöntem: Bu çalışmaya 01/01/2021 ile 01/10/2022 tarihleri arasında Sağlık Bakanlığı Ankara Şehir Hastanesi Perinatoloji kliniğinde değerlendirilen GİK tanılı hasta grubu (n=65) ve kontrol grubu (n=107) dahil edildi. Her iki grubun laboratuvar testleri retrospektif olarak incelendi. Grupların maternal demografik özellikleri, ilk trimester monosit sayıları ile lenfosit-monosit oranı (LMO), platelet-monosit oranı (PMO), bazofil-monosit oranı (BMO), nötrofil-monosit oranı (NMO) indeksleri karşılaştırıldı. GİK grubunda monosit sayıları ve monosit bazlı kan hücre indeksleri ile açlık safra asidi düzeyleri arasındaki ilişki değerlendirildi. GİK'i öngörmede ilk trimester monosit sayısı ve monosit bazlı kan hücre indeksleri için eşik değeri belirlendi.

Bulgular: GİK grubunda doğum haftası, doğum ağırlığı daha düşük ve yenidoğan yoğun bakım ihtiyacı daha yüksek ve istatistiksel olarak anlamlıydı (p < 0.05). GİK grubunda monosit sayısı daha yüksek (p=0.002), trombosit sayısı daha düşük (p=0.002) ve monosit bazlı tam kan hücre indeksleri sırasıyla NMO, LMO, PMO daha düşük ve istatistiksel olarak anlamlıydı (sırasıyla p=0.005, p=0.001, p<0.001).

Sonuç: Sonuç olarak, gebeliğin ilk trimesterinde daha yüksek monosit sayıları ve düşük monosit bazlı tam kan hücre indeks değerleri GİK ile ilişkili görünmektedir. Bu yeni indeksler, GİK'in ve bunun olumsuz perinatal sonuçlarının tahmininde kullanılabilir.

Anahtar Kelimeler: Gebelik, intrahepatik kolestaz, monosit, serum safra asidi

ABSTRACT

Aim: To evaluate the effect of monocyte count and monocyte-based whole blood cell indices in the prediction of intrahepatic cholestasis of pregnancy (ICP) in the first trimester.

Materials and Method: The clinical data of patients who presented to the Perinatology Clinic of the Turkish Ministry of Health Ankara City Hosiptal with ICP between January 1, 2021, and October 1, 2022, were evaluated retrospectively. Maternal demographic parameters, gestational age at birth, fetal birth weight, first-trimester white blood cell, neutrophil, platelet, monocyte, lymphocyte, and basophil counts, lymphocyte-to-monocyte ratio (LMR), platelet-to-monocyte ratio (PMR), neutrophil-to-monocyte ratio (NMR), and basophil-to-monocyte ratio (BMR) were recorded. These parameters were compared between the ICP and control groups. The relationship between monocyte count, monocyte-based blood cell indices, and fasting bile acid levels was evaluated in the ICP group. The cut-off values of the first-trimester monocyte count and monocyte-based blood cell indices for the prediction of ICP were determined.

Results: Gestational week at birth and fetal birth weight were significantly lower, and the neonatal intensive care requirement was significantly higher in the ICP group (p<0.05) compared to the control group. The ICP group had a significantly higher monocyte count (p=0.002), a significantly lower platelet count (p=0.002), and significantly lower values for monocyte-based complete blood cell indices (NMR, LMR, and PMR) compared to the control group (p=0.005, p=0.001, and p<0.001, respectively).

Conclusion: A high monocyte count and low monocyte-based inflammatory indices measured in the first trimester of pregnancy seem to be associated with ICP. These novel indices can be used in the prediction of ICP and its adverse perinatal outcomes.

Keywords: Pregnancy, intrahepatic cholestasis, monocytes, serum bile acid

Sorumlu Yazar/ Corresponding Author: Bedri SAKCAK Adres: University of Health Sciences Ankara City Hospital, Bilkent, 06800, Ankara, E-mail: drbedrisakcak@hotmail.com

Başvuru tarihi: 29.04.2023 Kabul tarihi: 13.11.2023

INTRODUCTION

Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease and is characterized by elevated serum aminotransferase levels. It develops during the second or third trimester of pregnancy and usually presents with itching and high bile acid levels. ICP resolves spontaneously within a few weeks after delivery (1, 2). In clinical practice, ICP may have a late diagnosis, resulting in delays in treatment.

Persistently high bile acid levels can lead to significant vasospasm of the placental villus surface, reduce the blood flow from the intervillous region of the placenta, and result in complications in both the mother and the fetus (3, 4). Therefore, the early diagnosis and treatment of ICP are very important. The pathogenesis of ICP is complex, and inflammation may play an important role. In the pathogenesis of ICP, an increase in the pathological concentration of bile acid can induce many inflammatory responses to in hepatocyte cells, leading to the production of many agents (5, 6).

Complete blood cell analysis is a simple and inexpensive test that is widely used to evaluate inflammatory processes and diagnose many diseases. During inflammation, the number of circulating monocytes increases, and most of these cells migrate to the site of inflammation and differentiate into exudate macrophages. Monocytes are circulating leukocytes that are important for innate and adaptive immunity and the functioning of immune defense, and are involved in inflammation and tissue remodeling. ICP is a multifactorial pregnancy-specific disease that includes many risk factors, such as genetic predisposition, chronic liver disease, and excessive inflammation. Therefore, increased inflammation in the first trimester of pregnancy may be associated with a higher ICP rate. Various studies have investigated the relationship between complete blood cell indices and obstetric complications, and such indices have been employed to predict the course and adverse outcomes of numerous diseases in other branches of medicine (7-9).

This study aimed to evaluate the role of the first-trimester monocyte count and monocyte-based complete blood cell indices in predicting the development, severity, and prognosis of ICP and determine whether these indices were correlated with the severity of the disease.

MATERIALS AND METHOD

The clinical data of patients who presented to the Perinatology Clinic of the Turkish Ministry of Health Ankara City Hospital with ICP between January 1, 2021, and October 1, 2022, were evaluated retrospectively. The study protocol was approved by the institutional ethics committee in terms of conformance to the principles of the Declaration of Helsinki, and approval was obtained from the clinical ethics committee of Ankara City Hospital (approval number: E2-22-2850).

A diagnosis of ICP was made based on the presence of unexplained, generalized pruritus, abnormal liver function test results serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >40 U/I), and a fasting serum bile acid level of above 10 mmol/l in pregnant women in the second or third trimester (10). In all cases, abdominal and hepatobiliary ultrasonographic imaging findings were normal, and viral hepatitis serology was negative for hepatitis. Pregnant women with systemic diseases, such as diabetes, hypertension, and kidney disease; smokers; women with multiple pregnancies; and pregnant women with fetal anomalies were excluded from the study. Maternal demographic parameters, gestational age at birth, fetal birth weight, first-trimester white blood cell, neutrophil, platelet, monocyte, lymphocyte, and basophil counts, lymphocyte-to-monocyte ratio (LMR), platelet-to-monocyte ratio (PMR), neutrophil-to-monocyte ratio (NMR), and basophil-to-monocyte ratio (BMR) were recorded. These parameters were compared between the ICP and control groups. First- and fifth-minute Apgar scores and neonatal intensive care requirements were also noted.

Statistical analysis

According to the analysis performed with ClinCalc, a total of 96 patients, 48 in each group, were required to achieve 95% power, p value of 0.05 (11). Statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS v. 22, IBM, SPSS for Windows, NY: IBM Corp.). Descriptive statistics were presented as median and interquartile range values for non-normally distributed variables. Median values were compared using the Mann–Whitney U-test for non-normally distributed data and Student's t-test used for normally distributed variables.

Finally, receiver operating characteristic (ROC) analysis was performed to determine the optimal cut-off value of the investigated parameters for the prediction of ICP. A p value of <0.05 was regarded as statistically significant.

RESULTS

The study included a total of 172 pregnant women (18-44 years), of whom 65 had ICP and 107 were healthy controls. There was no statistically significant difference between the two groups in terms of maternal age, fetal birth weight, gravidity, parity, body mass index (BMI), or first- and fifth-minute Apgar scores (p > 0.05). In the ICP group, gestational week at birth and fetal birth weight were significantly lower, and the neonatal intensive care requirement was significantly higher compared to the control group (p < 0.05) (Table 1).

	ICP group	Control group		
	(n = 65)	(n=107)	p value	
Maternal age	27(8)	28 (7)	0.766	
Gravidity	2 (2)	2 (2)	0.878	
Parity	0(1)	1 (1)	0.845	
BMI	27 (7)	28 (9)	0.103	
Gestational week at birth	37 (1)	38 (2)	<0.001*	
Fetal birth weight	2,750(570)	3,025 (630)	0.016*	
First-minute Apgar score	7(1)	7 (1)	0.132	
Fifth-minute Apgar score	9(1)	9(0)	0.799	
NICU requirement	24(36%)	12(11%)	0.009*	

Table 1: Maternal Demographic Parameters and Fetal and Neonatal Measurements

Note: Data given as median and interquartile range

Abbreviations: ICP, intrahepatic cholestasis of pregnancy; NICU, neonatal intensive care unit; BMI, body mass index.

White blood cell, neutrophil, lymphocyte, and basophil counts and the BMR did not statistically significantly differ between the two groups (p > 0.05). The ICP group had a significantly higher monocyte count (p=0.002), a significantly lower platelet count (p=0.002), and significantly lower values for monocyte-based complete blood cell indices compared to the control group (p=0.005, p=0.001, and p=0.000, respectively) (Table 2).

	ICP group	Control group (n =107)	p value	
	(n =65)			
WBC count	9.68 (3.98)	9.63 (2.56)	0.436	
Neutrophil count	6.96 (3.74)	7.19 (2.83)	0.726	
Lymphocyte count	1.83 (0.86)	1.87 (0.74)	0.903	
Monocyte count	0.54 (0.26)	0.44 (0.23)	0.002*	
Basophil count	0.020 (0.03)	0.020 (0.03)	0.509	
Platelet count	233 (73)	262 (97)	0.002*	
LMR	3.1818 (1.51)	4.2222 (2.15)	0.001*	
NMR	12.9048 (5.07)	14.5686 (6.67)	0.005*	
PMR	418.1818 (234.53)	571.4286 (334.39)	<0.001*	
BMR	0.50 (0.60)	0.513 (0.05)	0.798	

Note: Data given as median and interquartile range

Abbreviations: ICP, intrahepatic cholestasis of pregnancy; WBC, white blood cell; LMR, lymphocyte-to-monocyte ratio; PMR, plate-let-to-monocyte ratio; NMR, neutrophil-to-monocyte ratio; BMR, basophil-to-monocyte ratio.

1985

In the ICP group, the patients with a serum bile acid level of \geq 40 mmol/L had a higher monocyte count and lower monocyte-based complete blood cell indices than those with a serum bile acid level of < 40 mmol/L, but the differences between these two groups were not statistically significant (p> 0.05) (Table 3).

	Bile acid <40 mmol	Bile acid ≥40 mmol	p value
	(n=52)	(n=13)	
MONOCYTE	0.515 (0.3)	0.59 (0.23)	0.310
LMR	3.3537 (1.51)	2.9683 (1.45)	0.335
NMR	13.2562 (6.41)	12.1224 (3.99)	0.318
PMR	448.9044 (239.26)	367.1165 (276.18)	0.180

Table 3: Relationship Between Serum Bile Acid Levels and First-Trimester Maternal Blood Parameters in the ICP Group

Note: Data given as median and interquartile range

Abbreviations: ICP, intrahepatic cholestasis of pregnancy; LMR, lymphocyte-to-monocyte ratio; PMR, platelet-to-monocyte ratio; NMR,neutrophil-to-monocyte ratio.

Table 4 and Figures 1 and 2 present the results of the ROC analysis performed to determine the optimal cut-off values of first-trimester monocyte count and monocyte-based complete blood cell indices for the prediction of ICP.

Table 4: Results of the ROC Curve Analysis on the Performance of the First-Trimester Monocytes Count and Monocyte-Based Inflammatory Indices in Predicting ICP.

	Cut-off value	Sensitivity	Specificity	<i>p</i> value	
Monocyte count (AUC: 0.640, 95% CI: 553-728)	0.485	62%	62%	0.002*	
LMR (AUC: 0.647, 95% CI: .563731)	3.7190	63%	64%	0.001*	
PMR (AUC: 0.692, 95% CI: .612772)	481.2466	65%	66%	<0.001*	
NMR(AUC: 0.629, 95% CI: 552-716)	13.6098	63%	65%	0.005*	

Abbreviations: ROC, receiver operating characteristic; ICP, intrahepatic cholestasis of pregnancy; LMR, lymphocyte-to-monocyte ratio; PMR, platelet-to-monocyte ratio; NMR, neutrophil-to-monocyte ratio; AUC, area under the curve; CI, confidence interval.

Figure 1: Receiver Operating Characteristic (ROC) Curve Showing the Performance of the First-Trimester Monocyte Count in Predicting Intrahepatic Cholestasis of Pregnancy.



Figure 2: Receiver Operating Characteristic (ROC) Curve Showing the Performance of the First-Trimester Monocyte-Based Inflammatory Indices in Predicting Intrahepatic Cholestasis of Pregnancy.



DISCUSSION

In this study, we investigated the first-trimester maternal monocyte count and monocyte-based complete blood cell indices in patients with ICP and compared the results to a control group consisting of healthy pregnancies. When compared to the healthy control group, we found a significantly higher monocyte count and significantly lower values of monocyte-based complete blood cell indexes in patients with ICP, the most common liver disease that develops in pregnancy and has an inflammatory basis.

ICP complicates approximately 0.35–0.65% of pregnancies worldwide (12). Although the etiology of ICP has not yet been fully understood, it has been suggested that environmental effects, ethnic, genetic, and familial factors, geographic variations, activation of inflammatory cells, hormonal factors, and placental pathologies contribute to its pathogenesis (13, 14). Prediction and prevention of pregnancy-related complications are of great importance (15). It is known that there is an increased risk of preterm birth, an increased need for neonatal intensive care (NICU), and stillbirth in ICP, and these conditions increase as the maternal acid level increases (16).

In our study, the neonatal intensive care requirement was found to be statistically higher in the ICP group, as expected in newborns of pregnant women with cholestasis. However, no difference was found between the ICP and control groups in terms of Apgar scores. Numerous algorithms and guidelines have been proposed for the management of risk factors in ICP, and early diagnosis, treatment, and observation may help reduce fetal and maternal complication rates (17, 18).

According to previous studies, monocyte-based blood cell indices are relatively stable biomarkers of systemic inflammation (19). The traditional view on monocyte function is that monocytes are precursors to macrophages that extravasate into tissues and differentiate into professional antigen-presenting cells, where they are then able to resolve inflammation (20, 21). The depletion of monocytes at different stages of inflammation suggests that these cells play a critical role in mediating the resolution of the response (22, 23). Studies have shown that ICP is also an inflammatory process and that there is a relationship between inflammation markers and the severity of ICP. Recent studies indicate an association between complete blood cell indices and perinatal outcomes (24).

Increased bile acids are considered to cause fetal death by ca-

using fetal arrhythmia and sudden vasospasm in placental chorionic vessels (25). A meta-analysis reported that as the serum bile acid level increased, the rate of adverse perinatal outcomes also increased (26). Other studies have shown that pregnancies presenting with a maternal serum bile acid concentration of 40 µmol/L or higher are more likely to be complicated by spontaneous preterm birth, meconium amniotic fluid, fetal asphyxia, and fetal death, and there is a relationship between the maternal high serum bile acid concentration and stillbirth (27-29). Similarly, in a systematic review, the fetal death rates were found to be 0.4, 0.3, and 6.8% in pregnancies in which the total maternal bile acid concentrations were <40 mmol/L, 40-99 mmol/L, and \geq 100 mmol/L, respectively (30).

The degree of inflammation can be assessed using complete blood cell parameters and indices. In this study, we determined the cut-off values of monocyte-based complete blood cell indices and monocyte count in predicting patients with ICP. We also evaluated the relationship of the bile acid level with monocyte count and monocyte-based complete blood cell indexes in the ICP group. Although monocyte count was higher and monocyte-based complete blood cell indices were lower in the ICP subgroup with a serum bile acid level of \geq 40 mmol/L, this did not reach a statistically significant level. In the ICP subgroup with a high bile acid level (\geq 40 mmol/L), lower monocyte-based blood cell indices and a higher monocyte count are expected in terms of the relationship between ICP and adverse perinatal outcomes, and these findings are consistent with the literature (31, 32).

In liver biopsies of women with ICP, pathological findings, such as biliary plugs containing hepatocytes and canaliculi without dilatation or injury, as well as centrilobular cholestasis, have been detected, suggesting that ICP is a reversible disease (6, 33). Dal-Secco et al. showed that during sterile injury to the liver, proinflammatory monocytes were transformed into reparative monocytes at the injury site (34). Other researchers have, proposed that the risk of liver, biliary tract, pancreatic diseases, and hepatobiliary cancer increases in women with a history of ICP (35). Circulating monocytes may promote tumor growth and help tumor cells escape immune surveillance (36). Derived from circulating monocytes, tumor-associated macrophages have been reported to be able to infiltrate into the hepatocellular carcinoma matrix and promote proliferation, metastasis, and angiogenesis (37-39). However, long-term cohort studies are needed to establish a relationship between the risk of hepatobiliary disease or malignancy with high monocyte levels and

1987

low monocyte-based complete blood cell indices during pregnancy. The increased incidence of hepatobiliary malignancies in women with a history of ICP, the proliferation of monocytes in hepatic malignancies, and the support of angiogenesis suggest that there may be a relationship between ICP and monocytes.

The gold standard for the diagnosis of ICP is the fasting serum bile acid level. However, not all healthcare institutions perform this measurement, and there is a relatively long turn-around time for those that do. Therefore, alternative indexes, especially those that are easy to access and cost-effective and facilitate the timely evaluation of tests performed in almost every healthcare facility,may have significant clinical value for the evaluation of ICP.

To the best of our knowledge, this is the first study to investigate the role of the first-trimester monocyte count and monocyte-based inflammatory indices in ICP. We consider that our results will contribute to the literature. However, the relatively small number of patients, the single-center design, and the absence of long-term perinatal outcomes are the main limitations of this study. In this context, there is a need for randomized, controlled studies with a larger number of participants.

CONCLUSION

A high monocyte count and low monocyte-based inflammatory indices measured in the first trimester of pregnancy seem to be associated with ICP. These novel indices can be used in the prediction of ICP and its adverse perinatal outcomes.

REFERENCES

1. Allen AM, Kim WR, Larson JJ, Rosedahl JK, Yawn BP, McKeon K, et al. The Epidemiology of Liver Diseases Unique to Pregnancy in a US Community: A Population-Based Study. Clin Gastroenterol Hepatol. 2016;14(2):287-94.e1-2. Epub 20150821. doi: 10.1016/j.cgh.2015.08.022. PubMed PMID: 26305066; PubMed Central PMCID: PMC4718803.

 Lee RH, Goodwin TM, Greenspoon J, Incerpi M. The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J Perinatol. 2006;26(9):527-32. Epub 20060608. doi: 10.1038/sj.jp.7211545. PubMed PMID: 16761011.

3. Tayyar AT, Kozalı S, Yetkin Yildirim G, Karakus R, Yuksel IT, Erel O, et al. Role of ischemia-modified albumin in the evaluation of oxidative stress in intrahepatic cholestasis of pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine. 2019;32(22):3836-40.

4. Feng C, Li WJ, He RH, Sun XW, Wang G, Wang LQ. Impacts of different methods of conception on the perinatal outcome of intrahepatic cholestasis of pregnancy in twin pregnancies. Sci Rep. 2018;8(1):3985. Epub 20180305. doi: 10.1038/ s41598-018-22387-6. PubMed PMID: 29507303; PubMed Central PMCID: PMC5838236.

5. Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis. 2010;30(2):186-94. Epub 20100426. doi: 10.1055/s-0030-1253227. PubMed PMID: 20422500; PubMed Central PMCID: PMC3746018.

6. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol. 2011;178(1):175-86. Epub 20101223. doi: 10.1016/j.ajpath.2010.11.026. PubMed PMID: 21224055; PubMed Central PMCID: PMC3070591.

7. Carranza Lira S, García Espinosa M. Differences in the neutrophil/lymphocyte ratio and the platelet/lymphocyte ratio in pregnant women with and without COVID-19. Int J Gynaecol Obstet. 2022;157(2):296-302. Epub 20210807. doi: 10.1002/ijgo.13840. PubMed PMID: 34322880; PubMed Central PMCID: PMC9087599.

8. Hershko Klement A, Hadi E, Asali A, Shavit T, Wiser A, Haikin E, et al. Neutrophils to lymphocytes ratio and platelets to lymphocytes ratio in pregnancy: A population study. PLoS One. 2018;13(5):e0196706. Epub 20180522. doi: 10.1371/journal.pone.0196706. PubMed PMID: 29787560; PubMed Central PMCID: PMC5963784.

9. Tanacan A, Uyanik E, Unal C, Beksac MS. A cut-off value for systemic immune-inflammation index in the prediction of adverse neonatal outcomes in preterm premature rupture of the membranes. J Obstet Gynaecol Res. 2020;46(8):1333-41. Epub 20200601. doi: 10.1111/jog.14320. PubMed PMID: 32483902.

10. Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol. 2018;231:180-7. Epub 20181026. doi: 10.1016/j.ejogrb.2018.10.041. PubMed PMID: 30396107.

11. Zheng Q, Liu J, Ji Y, Zhang Y, Chen X, Liu B. Elevated levels of monocyte-lymphocyte ratio and platelet-lymphocyte

1988

ratio in adolescents with non-suicidal self-injury. BMC Psychiatry. 2022;22(1):618. Epub 20220919. doi: 10.1186/s12888-022-04260-z. PubMed PMID: 36123674; PubMed Central PM-CID: PMC9483869.

12. Cui D, Zhong Y, Zhang L, Du H. Bile acid levels and risk of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy: A meta-analysis. J Obstet Gynaecol Res. 2017;43(9):1411-20. Epub 20170710. doi: 10.1111/jog.13399. PubMed PMID: 28691322.

13. Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet journal of rare diseases. 2007;2(1):1-6.

14. Pataia V, Dixon PH, Williamson C. Pregnancy and bile acid disorders. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2017;313(1):G1-G6.

15. Tolunay HE, Eroğlu H, Varlı EN, Akşar M, Şahin D, Yücel A. Evaluation of first-trimester neutrophil-lymphocyte ratio and platelet-lymphocyte ratio values in pregnancies complicated by intrauterine growth retardation. Turkish Journal of Obstetrics and Gynecology. 2020;17(2):98.

16. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstetrics & Gynecology. 2014;124(1):120-33.

17. Tayyar AT, Tayyar A, Atakul T, Yayla CA, Kilicci C, Eser A, et al. Could first- and second-trimester biochemical markers for Down syndrome have a role in predicting intrahepatic cholestasis of pregnancy? Arch Med Sci. 2018;14(4):846-50. Epub 20170905. doi: 10.5114/aoms.2017.69865. PubMed PMID: 30002703; PubMed Central PMCID: PMC6040116.

18. Abide ÇY, Vural F, Kılıççı Ç, Ergen EB, Yenidede İ, Eser A, et al. Can we predict severity of intrahepatic cholestasis of pregnancy using inflammatory markers? Turkish journal of obstetrics and gynecology. 2017;14(3):160.

19. Mazza MG, Lucchi S, Rossetti A, Clerici M. Neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio in non-affective psychosis: A meta-analysis and systematic review. World J Biol Psychiatry. 2020;21(5):326-38. Epub 20190430. doi: 10.1080/15622975.2019.1583371. Pub-Med PMID: 30806142.

20. Crane MJ, Daley JM, van Houtte O, Brancato SK, Henry Jr WL, Albina JE. The monocyte to macrophage transition in the murine sterile wound. PloS one. 2014;9(1):e86660.

21. Peng X, Zhang J, Xiao Z, Dong Y, Du J. CX3CL1– CX3CR1 interaction increases the population of Ly6C– CX3CR1hi macrophages contributing to unilateral ureteral obstruction–induced fibrosis. The Journal of Immunology.

2015;195(6):2797-805.

22. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. The Journal of clinical investigation. 2005;115(1):56-65.

23. Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Müller W, et al. Differential roles of macrophages in diverse phases of skin repair. The Journal of Immunology. 2010;184(7):3964-77.

24. Lasser DM, Chervenak J, Moore RM, Li T, Knight C, Teo HO, et al. Severity of COVID-19 Respiratory Complications during Pregnancy are Associated with Degree of Lymphopenia and Neutrophil to Lymphocyte Ratio on Presentation: A Multicenter Cohort Study. Am J Perinatol. 2021;38(12):1236-43. Epub 20210716. doi: 10.1055/s-0041-1732421. PubMed PMID: 34396499.

25. Williamson C, Miragoli M, Sheikh Abdul Kadir S, Abu-Hayyeh S, Papacleovoulou G, Geenes V, et al. Bile acid signaling in fetal tissues: implications for intrahepatic cholestasis of pregnancy. Dig Dis. 2011;29(1):58-61. Epub 20110617. doi: 10.1159/000324130. PubMed PMID: 21691106.

26. Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393(10174):899-909. Epub 20190214. doi: 10.1016/s0140-6736(18)31877-4. PubMed PMID: 30773280; PubMed Central PMCID: PMC6396441.

27. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population@based case@control study. Hepatology. 2014;59(4):1482-91.

28. Herrera CA, Manuck TA, Stoddard GJ, Varner MW, Esplin S, Clark EA, et al. Perinatal outcomes associated with intrahepatic cholestasis of pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine. 2018;31(14):1913-20.

29. Rook M, Vargas J, Caughey A, Bacchetti P, Rosenthal P, Bull L. Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort. Plos one. 2012;7(3):e28343.

30. Di Mascio D, Quist-Nelson J, Riegel M, George B, Saccone G, Brun R, et al. Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review.

J Matern Fetal Neonatal Med. 2021;34(21):3614-22. Epub 20191119. doi: 10.1080/14767058.2019.1685965. PubMed PMID: 31744346.

31. Yayla Abide Ç, Vural F, Kılıççı Ç, Bostancı Ergen E, Yenidede İ, Eser A, et al. Can we predict severity of intrahepatic cholestasis of pregnancy using inflammatory markers? Turk J Obstet Gynecol. 2017;14(3):160-5. Epub 20170930. doi: 10.4274/tjod.67674. PubMed PMID: 29085705; PubMed Central PMCID: PMC5651890.

32. Luo M, Wang L, Yao H, Wen Y, Cao D, Shen W, et al. Diagnostic and prognostic value of blood inflammation and biochemical indicators for intrahepatic cholestasis of pregnancy in Chinese pregnant women. Sci Rep. 2022;12(1):20833. Epub 20221202. doi: 10.1038/s41598-022-22199-9. PubMed PMID: 36460663; PubMed Central PMCID: PMC9718819.

33. Peleg N, Issachar A, Sneh-Arbib O, Shlomai A. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. Dig Liver Dis. 2017;49(10):1133-8. Epub 20170511. doi: 10.1016/j.dld.2017.05.002. PubMed PMID: 28572039.

34. Dal-Secco D, Wang J, Zeng Z, Kolaczkowska E, Wong CH, Petri B, et al. A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury. Journal of Experimental Medicine.

2015;212(4):447-56.

35. Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomäki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology. 2006;43(4):723-8. doi: 10.1002/hep.21111. PubMed PMID: 16557542.

36. Hu Y-C, Yi Z-J, Zhou Y, Li P-Z, Liu Z-J, Duan S-G, et al. Overexpression of RIP140 suppresses the malignant potential of hepatocellular carcinoma by inhibiting NF-κB-mediated alternative polarization of macrophages. Oncology Reports. 2017;37(5):2971-9.

37. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218(11):1402-10.

38. Jackaman C, Tomay F, Duong L, Razak NBA, Pixley FJ, Metharom P, et al. Aging and cancer: The role of macrophages and neutrophils. Ageing research reviews. 2017;36:105-16.

39. Yan C, Yang Q, Gong Z. Tumor-Associated Neutrophils and Macrophages Promote Gender Disparity in Hepatocellular Carcinoma in ZebrafishRoles of Cortisol and TANs/TAMs in HCC Gender Disparity. Cancer Research. 2017;77(6):1395-407.